Man­u­fac­tur­ing is­sues hold back dis­tri­b­u­tion of over­dose in­jec­tion; San Diego biotech triples foot­print

In April, Pfiz­er was forced to stop pro­duc­tion of the in­jectable opi­oid an­ti­dote nalox­one, af­ter a man­u­fac­tur­ing is­sue. Now, a short­age has raised the alarm for ad­vo­cates, who are say­ing the lack of ac­cess cou­pled with an all-time high of drug over­dos­es could have dead­ly re­sults, The Wash­ing­ton Post re­ports.

Nalox­one is of­fered at a dis­count to harm pre­ven­tion pro­grams. These pro­grams are seek­ing do­na­tions to buy the drug at the mar­ket price of $20, or do­na­tions of near­ly-ex­pired dos­es. But Pfiz­er said it might be un­til Feb­ru­ary un­til it’s able to ad­e­quate­ly meet the de­mand of buy­ers, leav­ing or­ga­ni­za­tions in lim­bo to de­cide which fa­cil­i­ties it can stock, and what lo­ca­tions and or­ga­ni­za­tions get pri­or­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER